Below are the most recent publications written about "Sphingosine" by people in Profiles.
-
Glueck M, Koch A, Brunkhorst R, Ferreiros Bouzas N, Trautmann S, Schaefer L, Pfeilschifter W, Pfeilschifter J, Vutukuri R. The atypical sphingosine 1-phosphate variant, d16:1 S1P, mediates CTGF induction via S1P2 activation in renal cell carcinoma. FEBS J. 2022 09; 289(18):5670-5681.
-
Eckes T, Patyna S, Koch A, Oftring A, Gauer S, Oberm?ller N, Schwalm S, Schaefer L, Chun J, Gr?ne HJ, Pfeilschifter J. Sphingosine 1-Phosphate Receptor 5 (S1P5) Knockout Ameliorates Adenine-Induced Nephropathy. Int J Mol Sci. 2022 Apr 02; 23(7).
-
Vaidya M, Jentsch JA, Peters S, Keul P, Weske S, Gr?ler MH, Mladenov E, Iliakis G, Heusch G, Levkau B. Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages. J Lipid Res. 2019 03; 60(3):506-515.
-
Estella-Hermoso de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD, Blanco-Prieto MJ. Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia. J Biomed Nanotechnol. 2015 Apr; 11(4):691-701.
-
Rosini JM, Rajasimhan S, Fellows SE, Nomura JT. Delayed cardiac dysrhythmias after fingolimod administration. Am J Emerg Med. 2015 Jul; 33(7):987.e1-3.
-
Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia. 2014 Sep; 28(9):1915-8.
-
Egom EE, Rose RA, Neyses L, Soran H, Cleland JG, Mamas MA. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Crit Rev Clin Lab Sci. 2013 May-Jun; 50(3):79-89.
-
Huggins A, Sergott RC. Gilenya safety update: cardiac and macula. Curr Opin Ophthalmol. 2012 Nov; 23(6):457-9.
-
Huggins A, Sergott RC. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Curr Opin Ophthalmol. 2011 Nov; 22(6):447-50.
-
Egom EE, Mohamed TM, Mamas MA, Shi Y, Liu W, Chirico D, Stringer SE, Ke Y, Shaheen M, Wang T, Chacko S, Wang X, Solaro RJ, Fath-Ordoubadi F, Cartwright EJ, Lei M. Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol. 2011 Oct; 301(4):H1487-95.